Apollomics vs Kyntra Bio
APLM and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How APLM and KYNB compare
Kyntra Bio scores higher on the StockData Score (5 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | APLM | KYNB |
|---|---|---|
| Size and price | ||
| Market cap | – | $13.9M |
| Share price | $17.68 | $3.44 |
| Change, 1 year | 7.0% | −62.3% |
| Change, 5 years | – | −98.9% |
| Beta (5Y) | 0.68 | 1.24 |
| Employees | 14 | 34 |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 0.1× |
| P/S | – | 3.0× |
| FCF yield | – | −273% |
| Growth | ||
| Revenue growth (TTM) | – | −37.1% |
| Revenue growth, 5Y average | – | −48.4% |
| Profitability | ||
| Gross margin | – | 6.3% |
| Operating margin | – | −1090% |
| Net margin | – | 3968% |
| FCF margin | – | −824% |
| Financial health | ||
| Interest coverage | – | −5.4× |
| Current ratio | 0.96 | 2.69 (better) |
| Altman Z-score | – | −24.47 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 24.7% |
| Held by insiders | 76.0% | 15.7% |
| Insider net buying, 12 months | $8.3M (better) | $39.7K |
| Short interest, % of float | – | 2.8% |
Go deeper
- APLM stock overview
- APLM income statement
- APLM valuation and score
- KYNB stock overview
- KYNB income statement
- KYNB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.